News | September 26, 2025
Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr
BIL also holds an option to increase its equity stake by an additional 15%
BIL also holds an option to increase its equity stake by an additional 15%
It is intended for contrast enhancement in MRI scans
The company expects meaningful revenue contribution from this long-term agreement
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
